CLASS-LEADING TECHNOLOGY PLATFORM
MiRXES’ patented quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) technology platform enables sensitive, specific, and robust detection of microRNAs and other non-coding RNAs in biofluids and tissue samples.
Independently validated to be more sensitive than other RT-qPCR technology platforms for microRNA quantification.
KEY FEATURES
microRNA-specific forward and reverse real-time PCR primers confer further specificity and enable robust amplification.
Optimized RT and qPCR master mixes that enhance signal-to-noise ratio.
Increased Sensitivity
Optimized RT-qPCR primers and reagents ensure efficient target amplification from limited amounts (~1 pg) of input RNA.
Increased Specificity
No universal primers. Every assay utilizes three microRNA-specific primers to discriminate between microRNAs with single nucleotide differences.
Speedy
Detection
From RNA to Ct result in less than 2 hours.
Reliable
Data
Assays optimized by our proprietary algorithm and experimentally validated.
Convenience
Provided in a complete kit to minimize set-up time. Compatible with all major qPCR instruments.
Superior Sensitivity
These assays were shown to have more consistent performance across miRNAs with varying sequences especially those with high AT content.
Greater Reproducibility
This ease of use enables even first time users to generate consistent results from technical and biological replicates.
